Centessa Pharmaceuticals (CNTA) Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CNTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.65 |
| 52 Week High | US$19.09 |
| 52 Week Low | US$9.60 |
| Beta | 1.49 |
| 1 Month Change | 9.47% |
| 3 Month Change | 23.24% |
| 1 Year Change | 27.68% |
| 3 Year Change | 266.74% |
| 5 Year Change | n/a |
| Change since IPO | -23.45% |
Recent News & Updates
Recent updates
Centessa Pharmaceuticals (NASDAQ:CNTA) Is Using Debt Safely
Jul 17
Is There An Opportunity With Centessa Pharmaceuticals plc's (NASDAQ:CNTA) 50% Undervaluation?
Apr 19Does Centessa Pharmaceuticals (NASDAQ:CNTA) Have A Healthy Balance Sheet?
Mar 15Are Investors Undervaluing Centessa Pharmaceuticals plc (NASDAQ:CNTA) By 30%?
Jan 02Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring
Dec 31Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?
Nov 14Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
Sep 25Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?
Aug 15Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Shareholder Returns
| CNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | -1.1% | 1.9% |
| 1Y | 27.7% | -8.9% | 17.5% |
Return vs Industry: CNTA exceeded the US Biotechs industry which returned -8.9% over the past year.
Return vs Market: CNTA exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| CNTA volatility | |
|---|---|
| CNTA Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CNTA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 98 | Saurabh Saha | centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders.
Centessa Pharmaceuticals plc Fundamentals Summary
| CNTA fundamental statistics | |
|---|---|
| Market cap | US$2.23b |
| Earnings (TTM) | -US$230.37m |
| Revenue (TTM) | US$15.00m |
Is CNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTA income statement (TTM) | |
|---|---|
| Revenue | US$15.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.00m |
| Other Expenses | US$245.37m |
| Earnings | -US$230.37m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,535.82% |
| Debt/Equity Ratio | 31.8% |
How did CNTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 18:38 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Centessa Pharmaceuticals plc is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |